et al. International cooperation to improve access to and sustain effectiveness of antimicrobials. The Lancet. 2016;387(10015):296-307.
40 Seppala H, Klaukka T, Vuopio-Varkila J, Muotiala A, Helenius H, Lager K, et al. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. Finnish Study Group for Antimicrobial Resistance. N Engl J Med. 1997;337(7):441-6.
41 Chen DK, McGeer A, de Azavedo JC, and DE Low. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network. N Engl J Med. 1999;341(4):233-9.
42 European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2013. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). Stockholm: ECDC; 2014.
43 Sievert, Dawn M, et al. Antimicrobial-Resistant Pathogens Associated with Healthcare-Associated Infections Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009–2010. Infection Control; Hospital Epidemiology 2013;34(1).
44 Cosgrove SE, Qi Y, Kaye KS, Harbarth S, Karchmer AW, and Y Carmeli. The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges. Infect Control Hosp Epidemiol. 2005;26(2):166-74.
45 VGH Twele, Moyen LE, Zhang K., Dalton B, Church D, and J Conly. Methicillin-Resistant Staphylococcus aureus Endocarditis and de Novo Development of Daptomycin Resistance during Therapy. Can J Infect Dis Med Microbiol. 2010;21(2), 89-93.
46 Theodoros KT, and H Romney. Daptomycin Nonsusceptible Enterocci: An Emerging Challenge for Clinicians. Clin Infect Dis. 2011; 52(2): 228-234.
47 Lessa FC, Mu Y, Bamberg WM, Beldavs ZG, Dumyati GK, Dunn JR, et al. Burden of Clostridium difficile infection in the United States. N Engl J Med. 2015;372(9):825-34.
48 Loo VG, Poirier L, Miller MA, Oughton M, Libman MD, Michaud S, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med. 2005;353(23):2442-9.
49 Zimlichman E, Henderson D, Tamir O, Franz C, Song P, Yamin CK, et al. Health care-associated infections: a meta-analysis of costs and financial impact on the US health care system. JAMA Intern Med. 2013;173(22):2039-46.
50 Feazel LM, Malhotra A, Perencevich EN, Kaboli P, Diekema DJ, and ML Schweizer. Effect of antibiotic stewardship programmes on Clostridium difficile incidence: a systematic review and meta-analysis. J Antimicrob Chemother. 2014;69(7):1748-54.
51 Slimings C, and TV Riley. Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis. J Antimicrob Chemother. 2014;69(4):881-91.
52 He M, Miyajima F, Roberts P, Ellison L, Pickard DJ, Martin MJ, et al. Emergence and global spread of epidemic healthcare-associated Clostridium difficile. Nature genetics. 2013;45(1):109-13.
53 Owens RC, Jr., Donskey CJ, Gaynes RP, Loo VG, and CA Muto. Antimicrobial-associated risk factors for Clostridium difficile infection. Clin Infect Dis. 2008;46 Suppl 1:S19-31.
54 Stevens V, Dumyati G, Fine LS, Fisher SG, and E van Wijngaarden. Cumulative antibiotic exposures over time and the risk of Clostridium difficile infection. Clin Infect Dis. 2011;53(1):42-8.
55 Rajendran R, Sherry L, Deshpande A, Johnson EM, Hanson MF, Williams C, et al. A Prospective Surveillance Study of Candidaemia: Epidemiology, Risk Factors, Antifungal Treatment and Outcome in Hospitalized Patients. Front Microbiol. 2016;7:915.
56 Li C, Wang H, Yin M, Han H, Yue JF, Zhang F, et al. The Differences in the Epidemiology and Predictors of Death between Candidemia Acquired in Intensive Care Units and Other Hospital Settings. Intern Med. 2015;54(23):3009-16.
57 Lortholary O, Renaudat C, Sitbon K, Madec Y, Denoeud-Ndam L, Wolff M, et al. Worrisome trends in incidence and mortality of candidemia in intensive care units (Paris area, 2002-2010). Intensive Care Med. 2014;40(9):1303-12.
58 Van den Bosch CM, Geerlings, SE, Natsch S, et al. Quality indicators to measure appropriate antibiotic use in hospitalized adults. Clin Infect Dis. 2015;60:281-91.
59 Hughes JM. Study on the efficacy of nosocomial infection control (SENIC Project): results and implications for the future. Chemotherapy. 1988;34(6):553-61.
60 Public Health Agency of Canada. Essential Resources for Effective Infection Prevention and Control Programs: A Matter of Patient Safety - A Discussion Paper. In: Control CfCDaI, editor. Ottawa, ON: Health Canada; 2010.
61 Carignan A, Roussy JF, Lapointe V, Valiquette L, Sabbagh R, and J Pepin. Increasing risk of infectious complications after transrectal ultrasound-guided prostate biopsies: time to reassess antimicrobial prophylaxis? Eur Urol. 2012;62(3):453-9.
62 Demczuk W, Martin I, Peterson S, Bharat A, Van Domselaar G, Graham M, et al. Genomic Epidemiology and Molecular Resistance Mechanisms of Azithromycin-Resistant Neisseria gonorrhoeae in Canada from 1997 to 2014. J Clin Microbiol. 2016;54(5):1304-13.
63 Maslikowska JA, Walker SA, Elligsen M, Mittmann N, Palmay L, Daneman N, et al. Impact of infection with extended-spectrum beta-lactamase-producing Escherichia coli or Klebsiella species on outcome and hospitalization costs. J Hosp Infect. 2016;92(1):33-41.
64 Shore CK, and A Coukell. Roadmap for antibiotic discovery. Nat Microbiol. 2016;1(6):16083.
65 Rushton CH. Creating a Culture of Ethical Practice in Health Care Delivery Systems. The Hastings Center report. 2016;46 Suppl 1:S28-31.
Share with your friends: |